CompletedPhase 2NCT02301039

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sarcoma Alliance for Research through Collaboration
Principal Investigator
Hussein Tawbi, MD, PhD
M.D. Anderson Cancer Center
Intervention
Pembrolizumab(drug)
Enrollment
144 enrolled
Eligibility
12 years · All sexes
Timeline
20152020

Study locations (12)

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02301039 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma

← Back to all trials